In Focus



Pakistan Economy

February Inflation expected to moderate to 23.5% Y/Y from 28.4% in January 2024

We expect Headline Inflation to moderate to 23.5% in February 2024 from 28.4% in January 2024 through a combination of the base effect and lower food prices.

On a mid of the month SPI basis, prices for tomatoes and onions have declined 14% and 24% respectively while prices for eggs declined 41%. We expect Urban Food CPI to decline 0.8% M/M compared to a 3.3% increase in January. Similarly, we expect Rural Food CPI to decline 1.2% M/M compared to a 2.5% increase in January. On a Y/Y basis, this translates into 19.1% Food Inflation in February compared to 25.2% in January 2024.

The decline in food prices is being somewhat offset by a rise in energy prices. Petrol and HSD prices are up 6% and 4% respectively based on midmonth SPI data. This is contributing to 1.8%/1.9% Urban/Rural Transport Inflation in February 2024.

Had transport inflation been flat M/M, our February headline inflation estimate would have been 13 bps lower. Similarly, had food inflation been in-line with the 3-month average of 1.0 - 1.2% M/M, our Headline Inflation estimate would have been 100bps higher.

Going forward, we expect the current trend in food inflation to somewhat reverse due to Ramadan. However, largely due to the base effect, Headline Inflation should continue to trend downwards.

As highlighted in our February 15th note on "Higher For Longer interest rates", we continue to remain cautious given potential risks to inflation emanating from further adjustment in administered energy & electricity prices and second-order inflation impacts.

Given 6-month forward inflation of 18%, and a 3% interest rate differential, we see the current monetary policy stance as appropriate, with a cut potentially deferred into the second half of the calendar year.

	-	
Weight	Jan'24	Feb'24E
100.0%	28.4%	23.5%
30.4%	25.2%	19.1%
0.9%	82.4%	66.0%
8.0%	20.7%	20.3%
27.0%	37.1%	33.1%
4.1%	31.1%	26.6%
2.3%	21.9%	20.7%
6.1%	26.3%	14.8%
2.4%	20.2%	19.4%
1.7%	32.8%	30.4%
4.9%	14.2%	14.9%
7.4%	28.6%	23.8%
4.8%	28.8%	24.8%
	100.0% 30.4% 0.9% 8.0% 27.0% 4.1% 2.3% 6.1% 2.4% 1.7% 4.9% 7.4%	100.0% 28.4% 30.4% 25.2% 0.9% 82.4% 8.0% 20.7% 27.0% 37.1% 4.1% 31.1% 2.3% 21.9% 6.1% 26.3% 2.4% 20.2% 1.7% 32.8% 4.9% 14.2% 7.4% 28.6%

Thursday, February 29, 2024

SPI Items				
Top 5 Increase	Jan'24	Feb'24	MoM	
Bananas	122	136	12%	
Petrol Super	260	277	6%	
HSD	277	288	4%	
Pulse Moong	304	311	2%	
Cooked Daal	141	144	2%	
Top 5 Decrease				
Eggs	425	249	-41%	
Onions	229	173	-24%	
Tomatoes	154	133	-14%	
LPG Cylinder	3,384	3,187	-6%	
Potatoes	58	56	-4%	

Source: PBS, BMA Research

Syavash Pahore

Deputy Head of Research Tel: +44 7984 992801

E-mail: syavash.pahore@bmacapital.com

BMA Capital Management Ltd.



Disclaimer

This research report is for information purposes only and does not constitute nor is it intended as an offer or solicitation for the purchase or sale of securities or other financial instruments. Neither the information contained in this research report nor any future information made available with the subject matter contained herein will form the basis of any contract. Information and opinions contained herein have been compiled or arrived at by BMA Capital Management Limited from publicly available information and sources that BMA Capital Management Limited believed to be reliable. Whilst every care has been taken in preparing this research report, no research analyst, director, officer, employee, agent or adviser of any member of BMA Capital Management Limited gives or makes any representation, warranty or undertaking, whether express or implied, and accepts no responsibility or liability as to the reliability, accuracy or completeness of the information set out in this research report. Any responsibility or liability for any information contained herein is expressly disclaimed. All information contained herein is subject to change at any time without notice. No member of BMA Capital Management Limited has an obligation to update, modify or amend this research report or to otherwise notify a reader thereof in the event that any matter stated herein, or any opinion, projection, forecast or estimate set forth herein, changes or subsequently becomes inaccurate, or if research on the subject company is withdrawn. Furthermore, past performance is not indicative of future results.

The investments and strategies discussed herein may not be suitable for all investors or any particular class of investor. Investors should make their own investment decisions using their own independent advisors as they believe necessary and based upon their specific financial situations and investment objectives when investing. Investors should consult their independent advisors if they have any doubts as to the applicability to their business or investment objectives of the information and the strategies discussed herein. This research report is being furnished to certain persons as permitted by applicable law, and accordingly may not be reproduced or circulated to any other person without the prior written consent of a member of BMA Capital Management Limited. This research report may not be relied upon by any retail customers or person to whom this research report may not be provided by law. Unauthorized use or disclosure of this research report is strictly prohibited. Members of BMA Capital Management and/or their respective principals, directors, officers and employees may own, have positions or effect transactions in the securities or financial instruments referred herein or in the investments of any issuers discussed herein, may engage in securities transactions in a manner inconsistent with the research contained in this research report and with respect to securities or financial instruments covered by this research report, may sell to or buy from customers on a principal basis and may serve or act as director, placement agent, advisor or lender, or make a market in, or may have been a manager or a co-manager of the most recent public offering in respect of any investments or issuers of such securities or financial instruments referenced in this research report or may perform any other investment banking or other services for, or solicit investment banking or other business from any company mentioned in this research report. Investing in Pakistan involves a high degree of risk and many persons, physical and legal, may be restricted from dealing in the securities market of Pakistan. Investors should perform their own due diligence before investing. No part of the compensation of the authors of this research report was, is or will be directly or indirectly related to the specific recommendations or views contained in the research report. By accepting this research report, you agree to be bound by the foregoing limitations.

BMA Capital Management Limited and / or any of its affiliates, which operate outside Pakistan, do and seek to do business with the company(s) covered in this research document. Investors should consider this research report as only a single factor in making their investment decision. BMA Research Policy prohibits research personnel from disclosing a recommendation, investment rating, or investment thesis for review by an issuer/company prior to the publication of a research report containing such rating, recommendation or investment thesis.

Stock Rating

Investors should carefully read the definitions of all rating used within every research reports. In addition, research reports carry an analyst's independent view and investors should ensure careful reading of the entire research reports and not infer its contents from the rating ascribed by the analyst. Ratings should not be used or relied upon as investment advice. An investor's decision to buy, hold or sell a stock should depend on said individual's circumstances and other considerations. BMA Capital Limited uses a three tier rating system: i) Buy, ii) Neutral and iii) Underperform (new rating system effective Jan 1'18) with our rating being based on total stock returns versus BMA's index target return for the year. A table presenting BMA's rating definitions is given below:

Old rating system

Valuation Methodology

To arrive at our period end target prices, BMA Capital uses different valuation methodologies including

- Discounted cash flow (DCF, DDM)
- Relative Valuation (P/E, P/B, P/S etc.)
- Equity & Asset return based methodologies (EVA, Residual Income etc.)